ATHA News & Events

Athira Pharma files to sell 58.46M shares of common stock for holders

Athira Pharma has changed its name to LeonaBio, Inc. The name change aligns with the Company's transformative acquisition of rights to develop and commercialize lasofoxifene, a promising late-stage clinical asset for the potential treatment of metastatic breast cancer, currently in a Phase 3 trial. In connection with the name change, the Company will change its ticker symbol to "LONA." The Company's common stock will commence trading on The Nasdaq Capital Market under the new ticker symbol on January 12, 2026. "This marks an exciting and transformative period for our company and emphasizes our commitment to advancing a pipeline of innovative, late-stage assets both internally developed and strategically in-licensed with the goal of accelerating their path to market and maximizing their potential clinical and commercial impact," said Mark Litton, CEO. "At LeonaBio, we are building a pipeline with the potential to change lives and create enduring value. Our new name truly reflects our commitment to leadership, resilience, and innovation-qualities that define our expanded mission to deliver transformative therapies for patients battling diseases that need better treatment options."

Athira Pharma announced that it has entered into an agreement to acquire the rights for the development and commercialization of lasofoxifene, a clinical asset in a potentially registrational Phase 3 trial. The ongoing Phase 3 ELAINE-3 clinical trial is greater than 50% enrolled with data expected in mid-2027. Athira has acquired an exclusive global license from Sermonix Pharmaceuticals, Inc. for rights to develop and commercialize lasofoxifene, a selective estrogen receptor modulator for the potential treatment of metastatic breast cancer. In conjunction with this transaction, Athira also announced an upfront financing of $90 million in private placement financing of common stock and warrants, with the warrants providing, if exercised, up to an additional $146 million to support development of the new program through key clinical and regulatory milestones. The financing was co-led by Commodore Capital, Perceptive Advisors, and TCGX, with participation from ADAR1, Blackstone Multi-Asset Investing, Kalehua Capital, Ligand Pharmaceuticals, New Enterprise Associates, Spruce Street Capital, and 9vc. The Company anticipates the upfront financing will support lasofoxifene development through its topline data readout and key regulatory milestones, with sufficient capital for runway into 2028.